Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLCs registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cell and Gene-Based Approaches to Heart Failure

This article was originally published in Start Up

Executive Summary

In heart failure, neither drugs nor devices can address a cascade of interrelated biomolecular and hemodynamic processes. These ultimately result in increased heart muscle fatigue, adverse ventricular remodeling, continuing loss of left ventricular ejection fraction, and all the other conditions that have created, in 2006, a heart failure product industry with $2.8 billion in product revenues, according to Current and Emerging Technologies for the Management of Heart Failure in the US, a report recently published by Medtech Insight. Looking to the future, there are currently a number of academic research institutions and biotechnology companies focused on the prophylaxis, containment, and potential reversal of the progression of heart failure with cellular transplants and gene therapy designed to accomplish myocardial tissue repair.

Related Content





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts